Laparoscopic gastrojejunostomy versus duodenal stenting in unresectable gastric cancer with gastric outlet obstruction.
10.4174/astr.2017.93.3.130
- Author:
Sa Hong MIN
1
;
Sang Yong SON
;
Do Hyun JUNG
;
Chang Min LEE
;
Sang Hoon AHN
;
Do Joong PARK
;
Hyung Ho KIM
Author Information
1. Department of Surgery, Seoul National University Bundang Hospital, Seongnam, Korea. hhkim@snubh.org
- Publication Type:Original Article
- Keywords:
Gastrojejunostomy;
Stents;
Stomach neoplasms;
Gastric outlet obstruction;
Laparoscopy
- MeSH:
Body Weight;
Comorbidity;
Compliance;
Drug Therapy;
Gastric Bypass*;
Gastric Outlet Obstruction*;
Humans;
Laparoscopy;
Medical Records;
Nutritional Status;
Propensity Score;
Quality of Life;
Retrospective Studies;
Seoul;
Serum Albumin;
Stents*;
Stomach Neoplasms*
- From:Annals of Surgical Treatment and Research
2017;93(3):130-136
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To compare the outcome between laparoscopic gastrojejunostomy (LapGJ) and duodenal stenting (DS) in terms of oral intake, nutritional status, patency duration, effect on chemotherapy and survival. METHODS: Medical records of 115 patients, who had LapGJ or duodenal stent placement between July 2005 and September 2015 in Seoul National University Bundang Hospital, have been reviewed retrospectively. Oral intake was measured with Gastric Outlet Obstruction Scoring System. Serum albumin and body weight was measured as indicators of nutritional status. The duration of patency was measured until the date of reintervention. Chemotherapy effect was calculated after the procedures. Survival period and oral intake was analyzed by propensity score matching age, sex, T-stage, comorbidities, and chemotherapy status. RESULTS: Forty-three LapGJ patients and 58 DS patients were enrolled. Improvement in oral intake was shown in LapGJ group versus DS group (88% vs. 59%, P = 0.011). Serum albumin showed slight but significant increase after LapGJ (+0.75 mg/dL vs. −0.15 mg/dL, P = 0.002); however, there was no difference in their body weight (+5.1 kg vs. −1.0 kg, P = 0.670). Patients tolerated chemotherapy longer without dosage reduction after LapGJ (243 days vs. 74 days, P = 0.006) and maintained the entire chemotherapy regimen after the procedure longer in LapGJ group (247 days vs. 137 days, P = 0.042). LapGJ showed significantly longer survival than DS (220 vs. 114 days, P = 0.004). CONCLUSION: DS can provide faster symptom relief but LapGJ can provide improved oral intake, better compliance to chemotherapy, and longer survival. Therefore, LapGJ should be the first choice in gastric outlet obstruction patients for long-term and better quality of life.
